{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2815.1","value":"1.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \\[mg\\]) on Day 1 of each 21-day cycle.","id":"OG000","title":"Atezolizumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Included PK population, defined as patients who had received any amount of study drug and had at least one serum concentration result available at clinical data cutoff.","reportingStatus":"POSTED","timeFrame":"At least 90 days (maximum 150 days) after last dose of study drug (up to approximately 42 months)","title":"Atezolizumab Serum Concentration at Washout","type":"PRIMARY","unitOfMeasure":"ug/mL"}